We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer

By LabMedica International staff writers
Posted on 25 Mar 2025

Clear cell renal cell carcinoma (ccRCC) is the most prevalent type of kidney cancer, making up approximately 90% of cases. More...

Each year, around 400,000 individuals are diagnosed with ccRCC globally. About 20% of ccRCC patients who undergo surgery to remove their cancer will experience a recurrence within five years, with the majority of these relapses occurring within the first two years. At present, the primary method for monitoring patients is through periodic scans, typically CT scans, performed every 6 to 12 months, depending on the patient's risk level. However, a new urine test offers the potential to detect the recurrence of kidney cancer at an early stage, potentially eliminating the need for invasive scans and providing patients with faster access to treatment.

This test works by analyzing the unique profiles of specific sugar molecules known as glycosaminoglycans (GAGs), which are present in urine. These profiles make up the GAGome. The AURORAX-0087A (AUR87A) study, led by Lund University (Lund, Sweden), is investigating whether the GAGome test can accurately detect the return of ccRCC after surgery. The initial cohort of the study included 134 patients treated across 23 hospitals in the UK, EU, USA, and Canada. All patients had ccRCC that was confined to the kidney and treated with surgery, most commonly through a complete kidney removal. Following surgery, patients continued standard CT scan monitoring and also underwent a urine test every three months. Each urine sample was analyzed using mass spectrometry, generating a GAGome score out of 100.

After a follow-up period of up to 18 months, 15% of the patients experienced a recurrence of their cancer. The GAGome test showed high sensitivity in detecting recurrence, accurately identifying 90% of patients whose cancer had returned, while correctly ruling out just over half of those who remained cancer-free. These results were derived from a GAGome score threshold optimized at 12/100, where a score above 12 was considered positive and a score of 12 or below as negative. A positive result from the test indicated a 26% likelihood that the patient had a recurrence. In contrast, a negative GAGome score provided a highly reliable 97% chance that the patient was cancer-free. The higher the GAGome score, the more likely the positive result was an accurate reflection of cancer recurrence. According to the researchers, this level of accuracy rivals that of CT scans and offers several benefits over relying on scans alone.

“CT scans often pick up small lesions that aren’t large enough to biopsy, and we currently don’t know whether they are a sign of the cancer returning or not. Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit,” said lead researcher on the study, Saeed Dabestani, Associate Professor at Lund University. “If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. Based on the results we have so far, it’s likely that we could safely halve the number of scans that patients have to undergo.”

Related Links:
Lund University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.